S&P 500   3,000.84 (+0.37%)
DOW   27,039.43 (+0.14%)
QQQ   194.03 (+0.51%)
AAPL   235.40 (+0.44%)
FB   190.31 (+0.40%)
MSFT   141.20 (+0.56%)
GOOGL   1,250.87 (+0.63%)
AMZN   1,792.62 (+0.85%)
NVDA   196.06 (+0.95%)
MU   46.04 (+1.95%)
BABA   177.74 (+0.35%)
GE   8.91 (+0.00%)
TSLA   263.25 (+1.35%)
AMD   31.24 (+1.40%)
T   37.81 (+0.05%)
F   9.06 (-0.22%)
ACB   3.75 (+3.88%)
PRI   124.21 (+0.27%)
NFLX   304.91 (+6.51%)
BAC   30.25 (+0.27%)
GILD   65.60 (+0.38%)
DIS   131.26 (+0.31%)
S&P 500   3,000.84 (+0.37%)
DOW   27,039.43 (+0.14%)
QQQ   194.03 (+0.51%)
AAPL   235.40 (+0.44%)
FB   190.31 (+0.40%)
MSFT   141.20 (+0.56%)
GOOGL   1,250.87 (+0.63%)
AMZN   1,792.62 (+0.85%)
NVDA   196.06 (+0.95%)
MU   46.04 (+1.95%)
BABA   177.74 (+0.35%)
GE   8.91 (+0.00%)
TSLA   263.25 (+1.35%)
AMD   31.24 (+1.40%)
T   37.81 (+0.05%)
F   9.06 (-0.22%)
ACB   3.75 (+3.88%)
PRI   124.21 (+0.27%)
NFLX   304.91 (+6.51%)
BAC   30.25 (+0.27%)
GILD   65.60 (+0.38%)
DIS   131.26 (+0.31%)
Log in

Qiagen Stock Price, News & Analysis (NYSE:QGEN)

$28.18
+0.64 (+2.32 %)
(As of 10/17/2019 09:38 AM ET)
Today's Range
$27.88
Now: $28.18
$28.45
50-Day Range
$25.45
MA: $32.40
$34.69
52-Week Range
$25.04
Now: $28.18
$41.55
Volume153,831 shs
Average Volume2.13 million shs
Market Capitalization$6.35 billion
P/E Ratio21.03
Dividend YieldN/A
Beta0.85
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone31-77-355-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.50 billion
Cash Flow$2.54 per share
Book Value$11.69 per share

Profitability

Net Income$190.38 million

Miscellaneous

Employees4,952
Market Cap$6.35 billion
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.


Qiagen (NYSE:QGEN) Frequently Asked Questions

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

How were Qiagen's earnings last quarter?

Qiagen NV (NYSE:QGEN) announced its quarterly earnings data on Wednesday, July, 24th. The company reported $0.33 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.34 by $0.01. The firm earned $381.60 million during the quarter, compared to the consensus estimate of $386.37 million. Qiagen had a return on equity of 12.10% and a net margin of 12.94%. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 EPS. View Qiagen's Earnings History.

When is Qiagen's next earnings date?

Qiagen is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Qiagen.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its third quarter earnings guidance on Monday, October, 7th. The company provided EPS guidance of $0.35-0.36 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.36.

What price target have analysts set for QGEN?

15 equities research analysts have issued 12-month target prices for Qiagen's stock. Their forecasts range from $25.00 to $42.00. On average, they expect Qiagen's stock price to reach $34.86 in the next year. This suggests a possible upside of 23.7% from the stock's current price. View Analyst Price Targets for Qiagen.

What is the consensus analysts' recommendation for Qiagen?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Qiagen.

Has Qiagen been receiving favorable news coverage?

Media headlines about QGEN stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Qiagen earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Qiagen.

Are investors shorting Qiagen?

Qiagen saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 3,540,000 shares, a decrease of 17.9% from the August 30th total of 4,310,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 3.0 days. Currently, 1.6% of the company's shares are short sold. View Qiagen's Current Options Chain.

Who are some of Qiagen's key competitors?

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include Netflix (NFLX), Gilead Sciences (GILD), Twitter (TWTR), NVIDIA (NVDA), Boeing (BA), Exelixis (EXEL), Starbucks (SBUX), Activision Blizzard (ATVI), Booking (BKNG) and Intel (INTC).

Who are Qiagen's key executives?

Qiagen's management team includes the folowing people:
  • Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)
  • Dr. Barthold Piening, Sr. VP & Head of Global Operations (Age 61)
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel., Intellectual Property & Litigation and Sr. VP

Who are Qiagen's major shareholders?

Qiagen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.07%) and Crossmark Global Holdings Inc. (0.02%).

Which institutional investors are selling Qiagen stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Crossmark Global Holdings Inc..

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $28.18.

How big of a company is Qiagen?

Qiagen has a market capitalization of $6.35 billion and generates $1.50 billion in revenue each year. The company earns $190.38 million in net income (profit) each year or $1.34 on an earnings per share basis. Qiagen employs 4,952 workers across the globe.View Additional Information About Qiagen.

What is Qiagen's official website?

The official website for Qiagen is http://www.qiagen.com/.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]


MarketBeat Community Rating for Qiagen (NYSE QGEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel